A physician explains that the sale of nonprescription cosmeceuticals from a dermatology office should be done in a manner that is educational but non-threatening to patients.
A physician and a lawyer argue against a dermatology clinic switching from a small, reliable pathology lab to a large-scale pathology lab in order to receive volume discounts and increase profit.
Despite their added benefit in assisting physicians with clinical decision making, statistical prediction rules have not been widely used since their introduction in 1954.
A physician responds to a previous article about the differences between using a commercial laboratory and a smaller hospital or pathology group lab for dermatological tests.
Dr Noah Boton joins Ethics Talk to discuss his article, coauthored with Dr Jeffrey Larnard: “When Should Patients at the End of Life Get Antimicrobials?”
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.